Cargando…
Safety of infusing rituximab at a more rapid rate in patients with rheumatoid arthritis: results from the RATE-RA study
BACKGROUND: As recommended in the current prescribing information, rituximab infusions in patients with rheumatoid arthritis (RA) take 4.25 hours for the first infusion and 3.25 hours for subsequent infusions, which is a burden on patients and the health care system. We therefore evaluated the safet...
Autores principales: | Pritchard, Charles H, Greenwald, Maria W, Kremer, Joel M, Gaylis, Norman B, Rigby, William, Zlotnick, Steve, Chung, Carol, Jaber, Birgit, Reiss, William |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4035685/ https://www.ncbi.nlm.nih.gov/pubmed/24884454 http://dx.doi.org/10.1186/1471-2474-15-177 |
Ejemplares similares
-
Durability of Response to Tocilizumab Therapy in Rheumatoid Arthritis: Data from the US-Based Corrona Rheumatoid Arthritis Registry
por: Pappas, Dimitrios A., et al.
Publicado: (2021) -
Impact of rituximab on patient-reported outcomes in patients with rheumatoid arthritis from the US Corrona Registry
por: Harrold, Leslie R., et al.
Publicado: (2017) -
A rheumatoid factor paradox: inhibition of rituximab effector function
por: Jones, Jonathan D, et al.
Publicado: (2013) -
Infection rates in patients from five rheumatoid arthritis (RA) registries: contextualising an RA clinical trial programme
por: Yamanaka, Hisashi, et al.
Publicado: (2017) -
Patterns of Prednisone Use in Patients with Rheumatoid Arthritis Initiating Treatment with Tocilizumab in Routine US Clinical Practice
por: Pappas, Dimitrios A., et al.
Publicado: (2019)